Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions.

1. Introduction

Immunomodulatory drug delivery systems (IDDSs) are innovative smart nanocarriers that are intrinsically utilized for the targeted and controlled modulation of the immune system. Immunomodulating agents such as cytokines, antibodies, and vaccines are employed to enhance efficacy and safety while minimizing adverse effects. This is achieved by delivering these agents directly to immune cells or target tissue [ 1 , 2 , 3 ]. Immunomodulatory DDSs have demonstrated significant efficacy in a wide range of diseases including cancer, autoimmune disorders, and infectious diseases. Specifically, it enables the direct delivery of therapeutic agents to cancer cells, promotes tumor response, and reduces the harmful side effects of immunotherapy drugs for cancer treatment [ 4 ]. IDDSs have also shown promising results by effectively delivering drugs for the treatment of rheumatoid arthritis (RA) [ 5 ]. As IDDSs are still in the early stages of development, they offer numerous advantages for drug delivery compared to traditional methods. Only a small volume of the drug is required, allowing local administration at therapeutic dosages. As a result, systemic toxicity is minimized, either because of the inability to reach therapeutic concentrations systemically, or the ability to use lower drug doses. This targeted approach enhances drug effectiveness by precisely targeting immune cells or tissues [ 6 , 7 ], while minimizing adverse effects, thus improving the risk–benefit ratio [ 6 ]. Moreover, IDDSs may improve patient compliance and adherence to treatment regimens [ 8 ].

IDDS represents an inaugural discipline within the field of pharmaceutical research that unites immunology with drug delivery applications to develop groundbreaking therapeutic strategies [ 9 ]. By precisely modulating immune responses, it has the potential to improve treatment effectiveness and overcome the constraints associated with conventional interventions to fine-tune the immune responses in a targeted manner. This innovative breakthrough has generated heightened enthusiasm for harnessing our understanding of the immune system for therapeutics. In alignment with this objective, IDDSs leverage the manipulation of the immune system to attain augmented treatment efficacy [ 3 , 10 ].

Additional methods of drug delivery involve the use of NP-based drug carriers, specifically, liposomes or polymeric NPs. These carriers were specifically designed to facilitate targeted delivery, allowing precise control over drug encapsulation and release. This targeted approach minimizes off-target effects and maximizes therapeutic effectiveness [ 11 , 12 ]. Furthermore, the utilization of immunotherapeutic strategies in conjunction with IDDSs presents a promising solution for overcoming resistance to cancer therapy and counteracting the immune-suppressing mechanisms associated with cancer [ 13 , 14 ]. As a result, these advancements offer hope that extends beyond the limitations currently faced in the field of immunotherapy [ 15 , 16 ] thereby overcoming obstacles to immunotherapy potential [ 17 , 18 ].

However, the development of IDDSs poses challenges in maintaining immune modulation without causing significant disruption, or in understanding the immune regulation and associated effects of these immunomodulatory agents [ 17 ]. The potential of IDDSs relies on overcoming challenges in material science, comprehending immunological aspects, understanding immune regulation, and understanding the impact of immunomodulatory agents [ 18 ]. The term IDDS encompasses a shared space in the fields of immunology and pharmaceutical innovation, where researchers and clinicians collaborate to explore the future possibilities of therapeutics [ 11 , 19 ]. In this context, IDDSs involve the utilization of nanocarriers, such as synthetic microparticles, liposomes, and chitosan, to enhance the body’s response to immunization [ 20 ]. Therefore, integrating the technical aspects of drug delivery into cancer immunotherapy holds great potential for introducing a new era of safe and effective treatment approaches that offer novel combinations of treatment and personalized cancer immunotherapy [ 21 ].

Combinatorial immunotherapy, such as chemotherapy and immunotherapy, acts synergistically to potentiate antitumor immune responses. Mechanistically, chemotherapy works through direct cytotoxic effects, induction of immunogenic cell death, and modulation of immune regulatory pathways, thus complementing the enhancement of antitumor immune responses via immunotherapy [ 22 ]. Clinical observations have shown improved response and survival rates for some cancers. Dose and scheduling issues are paramount for balancing the maximal efficacy, minimal toxicity, and immune-related adverse events. Similarly, combining phototherapy with immunotherapy, such as photodynamic therapy (PDT) and photothermal therapy (PTT), increases immune activation through activation of tumor-specific and systemic antitumor responses [ 22 ]. The optimization of treatment parameters and the identification of predictive biomarkers for patient selection are challenging. Other combinatorial approaches include radiation therapy, targeted therapy, and cytokine therapy with immunotherapy, and all possess unique synergistic interactions that can improve cancer treatment outcomes [ 22 ]. Such approaches represent one of the most exciting opportunities for boosting the efficacy of combinatorial immunotherapies by acting effectively as carriers of therapeutic agents with targeted delivery at the tumor site. The tunable characteristics of mesoporous silica NPs make them attractive candidates for the optimization of treatment parameters and help overcome related challenges in combinatorial immunotherapy, allowing improvement in cancer treatment.

In summary, IDDSs represent a promising approach to immunomodulatory drug delivery, providing precise targeting, improved efficacy, and enhanced safety. However, ongoing research is essential to fully unlock the potential of revolutionizing disease treatment strategies [ 23 , 24 ]. The safety concerns regarding nanomaterials in immunotherapy are principally related to their unique properties and interactions with biological systems. Biocompatibility is the single most important factor for addressing negative reactions, and knowledge of biodistribution helps understand the prevention of toxicity. Assessment of immunogenicity is critical and long-term safety evaluations are required to identify possible risks. Environmental impact and the possibility of meeting regulatory requirements are other factors of general concern. In general, these methods require full preclinical characterization, extensive toxicity testing, and active safety monitoring in clinical trials [ 25 , 26 ]. Each type of nanomaterial has advantages and disadvantages that dictate the preference for one type over another, as presented in Table 1 .

The present review outlines the exciting and fast- progressing IDDS field using nanomaterials for the precise and targeted modulation of the immune system. Herein, we describe the detailed interplay between nanomaterials and immune cells, which is considered a prerequisite for tailored modulation of immune responses in therapeutic applications. This study aimed to correlate the properties of nanomaterials with their specific applications in diseases, such as cancer, autoimmunity, and allergy, thus providing insight into the innovative potential of nanotechnology in immunotherapy. Nanomaterials selected for these diseases should satisfy certain criteria to meet the efficacy and specificity of therapeutic applications. Nanomaterials intended for targeting cancer cells typically have features designed to ensure their selective accumulation in tumors along with an adequate structure or composition that reduces off-target effects. These approaches vary from surface modifications that improve tumor cell homing and penetration, to payloads that can elicit cytotoxic effects once internalized within cells [ 27 ]. Nanomaterials have been used to regulate immune responses in autoimmunity, which requires accurate immunomodulatory properties that can regulate aberrant immune reactions. These materials are often used for surface functionalization to permit interaction with immune cells for the delivery of immunosuppressive agents or antigens to induce tolerance. Nanomaterials can be used to target key players in the allergic cascade to prevent or reduce hypersensitivity responses [ 28 ]. Typical examples of such applications include liposomes for the encapsulation of drugs targeted specifically to cancer cells, or for carrying immunomodulatory agents for autoimmunity. These therapeutic strategies include engineering polymeric NPs for the controlled release of allergen-specific treatments. Ultimately, nanomaterials are selected for their designed features, such as size, surface chemistry, and payload capacity, to optimize the therapeutic outcomes in the unique pathophysiology of each disease state. Engineered nanomaterials can be tailored to specifically interact with immune cell receptors or signaling pathways responsible for allergic reactions to modulate immune activation and subsequently diminish allergic responses. For example, NPs such as liposomes or polymeric NPs can be used to encapsulate allergens or immunomodulators such that they can be selectively delivered to immune cells at allergic inflammatory sites [ 29 ]. For example, advanced nanotechnologies are aimed at harnessing nanomaterials in allergen desensitization strategies, including allergen-specific immunotherapy (AIT). NPs can be designed based on the shape of the allergen structure or loaded with an allergen peptide for controlled delivery, which induces immune tolerance upon administration to reduce allergic sensitization over time. Nanomaterials may also be useful in designing novel strategies to modulate immune responses to prevent allergies. This is achieved through immune activation by locally delivering anti-inflammatory agents or immunomodulators to regulate immune cell activation. Using the distinctive properties of nanomaterials, the treatment of allergies has been revolutionized providing personalized and effective management of several different types of allergic diseases [ 30 , 31 ]. Table 2 summarizes a comparison of currently available immunotherapy paradigms.

In the present study, we conducted a thorough SWOT analysis of nanomaterial-based IDDSs. These systems combine nanotechnology with immunology, and have versatile applications in precision medicine ( Table 3 ). This analysis highlights the advantages of these systems, including precise targeting and enhanced efficacy through controlled release of immunomodulatory agents. However, it also acknowledges the challenges in their design and potential toxicity concerns, emphasizing the need for safety assessment. This study also discusses promising prospects such as personalized medicine, interdisciplinary collaborations, and combination therapies. However, it is important to consider potential threats such as regulatory obstacles, manufacturing complexities, and immunogenicity. By considering both internal and external factors, this study emphasizes the transformative potential of nanomaterial-based systems in revolutionizing immunotherapy and disease treatment strategies.

2. Immunomodulatory Strategies in Drug Delivery

The most important parameter for optimizing the design of IDDSs for molecular systems and receptors is the addition of surface ligands or antibodies, thereby showing selective interaction with molecular markers or receptors expressed on the surface of target cells [ 32 ]. It has the potential to contribute to an increase in the specificity of targeting and improvement in cellular uptake. Furthermore, biocompatibility ensures that the IDDS is minimally toxic and friendly to biological systems, and the controlled release mechanisms optimize the modulation of drug concentrations at the target site to yield the maximum therapeutic outcome [ 33 ]. Stability under physiological conditions ensures structural integrity and drug encapsulation within the IDDS, which circulates in the body without premature drug release or degradation [ 34 ]. Furthermore, the size and shape of IDDS considerably affect cellular uptake and biodistribution. In most instances, IDDSs at the nanoscale have better penetration across biological barriers and cellular internalization. Charged surface properties, such as zeta potential, equally play a role in affecting the stability, circulation time, and binding of IDDSs to target cells, and critically influence the in vitro and in vivo characteristics of IDDSs. The degradability of IDDS in a controlled manner after drug release ensures minimal long-term accumulation and potential toxicity. Such characteristics can be incorporated into the design of IDDSs so that effective, specific, and efficient IDDSs can be designed for various applications [ 35 , 36 ].

2.1. Targeting Immune Cells

Current innovations in this new field of combinatorial pharmacological interventions, along with immune responses, are ongoing, particularly to enhance drug delivery precision [ 12 ]. Over time, there has been increasing interest in the development of intracellular drug delivery systems targeting immune cells with acumen [ 37 ]. Such an IDDS, upon interaction with immune cells, can modulate immune responses at the cellular level for more effective delivery of therapeutic modalities. Another necessary factor for the successful implementation of an IDDS is immune cell tracking. For instance, nanocarriers such as liposomes or polymeric NPs have been engineered to incorporate therapeutic agents [ 38 , 39 ]. Thus, with the specificity of targeting immune cells and incorporating therapeutic agents within nanocarriers, it has been postulated that IDDSs offers a promising approach for treating immune-related disorders and diseases [ 18 ].

Among the antigen-presenting cells in the immune system, dendritic cells (DCs) are particularly significant as they capture antigens and activate T cells, thus initiating immune responses [ 40 ]. Targeting DCs can direct specific immune reactions. Nanocarriers coated with ligands that recognize DC-specific markers, such as CD11c and CD205, facilitate the uptake of immunomodulatory substances by DCs as shown in Figure 1 . These interactions trigger antigen presentation and T-cell activation, subsequently regulating immune processes [ 41 , 42 ]. Targeted delivery has proven successful in generating enhanced immune responses against pathogens and cancers [ 43 ].

Furthermore, macrophages can be categorized into two distinct functional states, M1 and M2, which respond differently to various stimuli, including specific cytokines and cellular mediators [ 44 ]. Macrophages are crucial for both inflamed tissues and tissue homeostasis. Nanocarriers designed to deliver medications are equipped with specific ligands that recognize surface markers on macrophages, such as CD64 and CD206. This targeted delivery ensures precise localization and action at the desired site, allowing immunomodulatory drugs to reverse inflammation through immune evasion strategies and induce tissue remodeling [ 45 , 46 ]. Nanocarriers, including liposomes, polymeric NPs, and mesoporous silica NPs, can be designed for targeted drug delivery to macrophages and T-cells ( Figure 1 ). The surfaces of nanocarriers can be functionalized with ligands that specifically recognize surface markers overexpressed in immune cells, such as CD64 and CD206 for macrophages and CD3 and CD28 for T-cells. Functionalization with such ligands ensures that the nanocarriers, at a minimum, bind selectively to target immune cells, to localize and release drugs at the site of interest [ 47 ]. The mechanism of action involves targeted delivery of immunomodulatory drugs to immune cells via nanocarriers. However, drug targeting is non-specific. Targeted delivery of drugs to immune cells through nanocarriers brings the drug to the targeted site, evoking immune modulation and resulting therapeutic response. Off-target effects and systemic exposure are minimized when drug targeting, as in this example, is designed to elicit a greater therapeutic effect. The nanocarrier acts as a vehicle, bringing drugs to immune cells, and the drugs exert their effects at the targeted site, evoking immune modulation, and resulting in therapeutic responses. Research has also revealed that some nanocarriers can act as drug delivery systems for immune cell targeting. For instance, Majumder and Minko [ 47 ] elaborated on the benefits of developing a nanocarrier-based delivery system as a remedy, bypassing conventional drug dosage formulation, with a special focus on targeted delivery at the disease site. For example, Elzoghby et al. illustrated the use of nanocarriers functionalized with lactoferrin for tumor-targeted drug delivery, demonstrating the potential of nanocarriers in targeted therapy. In essence, delivery to immune cells, such as macrophages and T-cells, is made possible using nanocarriers [ 48 ]. Appropriate modification of nanocarrier surfaces with specific ligands can provide immune cells with high target selectivity, leading to effective immunomodulatory drug delivery that modulates immune responses. The importance and efficiency of nanocarriers in achieving drug delivery for immunomodulation have been emphasized in these studies.

T-cells play a crucial role in adaptive immunity by orchestrating the immune response against pathogens and neoplasms. They can be engineered to provide therapeutic benefits through immune checkpoint blockade or CAR T cell therapy ( Figure 2 ) [ 49 , 50 ]. Nanocarriers decorated with modified ligands that target T cell receptors and co-stimulating molecules, such as CD3 and CD28, enable specific delivery of their contents [ 51 ]. This targeted delivery enhances T-cell activation, proliferation, and cytokine production, thereby enhancing the effectiveness of immunotherapy [ 18 ]. Nanomaterials possess desirable properties, such as chemical stability and inertness, which make them suitable carriers for delivering drugs to immune cells. For instance, liposomes coated with CD11c antibodies and loaded with antigens can specifically reach DCs [ 52 , 53 ]. Liposomes have been designed to deliver drugs to antigen-presenting dendritic cells (DCs). Chemical stability and inertness are the advantages of liposomes; therefore, they can be used as carriers for drug delivery to immune cells. Consequently, liposomes protect drugs against degradation, attain controlled release, enhance pharmacokinetic ability, and, most importantly, reach the desired immune cells via passive targeting [ 54 ]. This is based on the design of liposomes coated with CD11c antibodies that interact with the CD11c/CD18 integrins on the surface of DCs. Surface modification of liposomes has been proven to allow the specific recognition and conjugation of liposomes to DCs for specific drug delivery to immune cells [ 55 ]. Its mechanism of action involves receptor-mediated endocytosis, in which DCs internalize antigens loaded into liposomes and are coated with CD11c antibodies. Inside the cells, antigens released by liposomes are processed for presentation to T-cells, resulting in the induction of an immune response. This delivery specificity ensures that antigens reach DCs directly, thus inducing immune responses specific to the intended antigens [ 55 ]. Some studies have shown that the potential of immunoliposomes for targeted drug delivery occurs through selective delivery of encapsulated drugs to cells via the interaction of cell surface proteins using liposomes modified with antibodies [ 56 ]. Subsequent studies have dealt with more specifically targeted, drug-loaded liposomes functionalized with monoclonal antibodies (mAbs) to target antigens expressed on the cell surface, demonstrating the flexibility and specificity of antibody-coated liposomes for drug delivery [ 57 ].

In various disease models, targeted delivery of immunomodulators to M2 macrophages has been achieved using mesoporous silica NPs functionalized with mannose ligands. Engineered NPs carrying encapsulated immunomodulatory cytokines have also been explored for T-cell-targeted immunotherapies with the potential for further development in this field [ 58 ].

The field of immunomodulatory drug delivery has entered a new phase called precision medicine, in which targeted interventions using immune-cell-targeting techniques have become possible, as presented in Table 4 . The fusion of nanotechnology and immunology provides researchers with tools to induce immune responses for therapeutic purposes [ 59 ]. Immune-cell-targeting techniques have allowed immunomodulatory drug delivery for potential precision medicines, with the increasing feasibility of targeted interventions. The strategy is oriented toward individual patients with specific genetic makeup, lifestyle, and environment. The immune-cell-targeting permits precise control of the immune response and outcome of therapy [ 60 , 61 ].

However, it is essential to refine targeting strategies, optimize nanocarrier design, and establish the clinical efficacy of IDDSs. This requires a thorough understanding of immune cell biology, ligand–receptor interactions, and immune cascades [ 62 ]. Through a combination of system immunology and advanced imaging techniques, the complexities of interactions between immune cells can be uncovered, leading to the development of more effective and safer IDDSs. Collaboration across different disciplines will play a crucial role in translating these advancements into tangible clinical applications, ultimately paving the way for personalized immunomodulation. Imaging plays an important role in immunotherapy [ 63 ] by encapsulating imaging agents, such as fluorescent dyes or contrast agents, for different imaging modalities, such as magnetic resonance imaging, computed tomography imaging, positron emission tomography, and optical imaging [ 64 ]. Additionally, these techniques enable the in vivo visualization and monitoring of nanomaterial distribution, accumulation, and clearance following administration to ensure effective targeted delivery at the tumor site with minimum off-target effects [ 65 ]. Moreover, imaging techniques allow the real-time assessment of therapeutic efficacy because of insights into the interactions of nanomaterials with the immune system and their effects on tumor growth and immune responses. This allows for early detection of response or resistance to treatment, enabling treatment decisions and timely adjustment of therapy regimens [ 66 ].

2.2. Modulating Immune Signaling Pathways

Immunotherapy and the shift towards precise modulation of the immune response have recently received much attention [ 94 ]. This development has advanced strategies that previously utilized nanomaterials in immunotherapy to acquire complex tools for controlling immune signaling pathways, which could potentially address previously untreatable diseases [ 44 , 79 ]. Nanomaterials can provoke immunological signaling through physical and chemical cues, penetrating immune pathways and processes associated with chemical carcinogenesis, MAPK signaling, cGMP-PKG signaling, cAMP signaling, and focal adhesions [ 95 ]. Similarly, the Wnt/β-catenin pathway not only supports immune responses but also modulates immune response elevation in anti-cancer strategies, thereby fine-tuning the balance between pro- and anti-inflammatory cytokines [ 96 ]. Viral proteins remodel innate immune signaling pathways to direct host antiviral responses [ 10 ]. In D. melanogaster , the cGMP-dependent signaling pathway regulates NF-κB in the immune system. Engineered NPs exhibit a heightened ability to target DCs and promote the development of a tolerogenic phenotype during the induction of immune tolerance [ 97 , 98 ]. Table 5 summarizes the diverse mechanisms and pathways that offer promising targets for the therapeutic regulation and intervention of the immune system.

The intrinsic nature of nanomaterials ensures targeted immune signaling, resulting in desired immunomodulatory effects. Furthermore, a variety of nanomaterials can be utilized to stimulate or suppress the immune system owing to their surface chemistry, which offers a significant potential for immune system modulation [ 21 ]. Such intrinsic properties of nanomaterials are related to targeted immune signaling, which achieves desired immunomodulatory effects. The control of immune system activity to achieve the desired immunomodulatory effect largely depends on the surface chemistry of the nanomaterials and their interactions with immune cells and biological molecules [ 99 ]. Their purpose may be to stimulate or depress the immune system, which can be manipulated using the surface chemistry of the nanomaterials. For example, surface modifications with ligands or antibodies targeting immune cell receptors allow for selective immune cell activation or inhibition. In addition, the physicochemical properties of nanomaterials, such as their size, shape, and charge, determine their interactions with immune cells and the penetration ability of biological barriers. In general, knowledge of how the physicochemical features of nanomaterials interact with immune system responses is necessary for designing activities in the most effective way for the therapeutic applications of IDDSs [ 60 , 100 ].

Future development includes optimized NPs capable of controlling, sustaining, and releasing antitumor or anticancer drugs as well as bioimaging tracers under high internal physiological hostility [ 101 ]. Moreover, nanomaterial-based immunotherapy has recently led to the discovery of a self-driven immune activation method in tumor tissues to prevent adverse immune responses [ 102 ]. In contrast, miRNAs modulate key immune signaling pathways by altering the expression of targeted immune system processes and pathways [ 103 ]. The successful development of engineered miRNA-based nanomaterials has been instrumental in cancer treatment, specifically in terms of immunomodulation and its effect on the responsiveness of immune cells in cancer immunotherapy [ 23 ]. Other potential beneficial effects include specific tumor-killing effects, enhanced immune cell access to crucial metastatic sites, optimized antigen presentation, and induction of idiopathic immune responses [ 104 ]. Covalent immobilization of nanomaterials with miRNAs is a promising approach for modulating immune signaling pathways. The utilization of nanomaterials and miRNAs in the formulation of targeted immunotherapies represents an improvement of the limitations of conventional therapy [ 24 , 105 ]. In addition to expanding the therapeutic repertoire, the delivery of miRNAs using nanomaterials is expected to address some of the disadvantages of conventional therapies, such as off-target effects and the development of resistance. Such engineered nanomaterials may precisely target immune signaling pathways to enhance treatment efficacy while limiting side effects, thus offering a new era in immunotherapy with personalized and tailored strategies [ 106 ].

2.3. Nanomaterials and the Intricate Network of Immune Signaling Pathways

Effective modulation of immune signaling pathways, such as the regulation of cytokines and inhibition of immune checkpoints, can be achieved using nanomaterials including liposomes and polymer-based NPs [ 99 ]. These nanomaterials are designed to achieve therapeutic goals by enabling controlled and sustained release of immunomodulatory agents [ 10 , 99 , 107 ]. It is crucial to note that the controlled release kinetics of these agents are of utmost importance as they determine therapeutic efficacy while minimizing potential adverse effects [ 3 ]. Moreover, the surface properties of nanocarriers can be modified after their administration at the target site through functionalization with ligands or antibodies. These modifications facilitate effective interactions with immune cells or selective tissues, thereby inducing an immunological response [ 107 ]. The choice of carrier material, such as NPs, significantly affects cargo capacity, release kinetics, and biocompatibility. For instance, mesoporous silica NP- encapsulated interleukin-10 (IL-10) has been utilized to modulate the level of inflammation and associated cascades in autoimmune diseases [ 108 , 109 ]. Furthermore, mesoporous silica NPs were chosen for the encapsulation of IL-10 mainly because of a few significant features that make them particularly suitable for use in controlling inflammation within an autoimmune disease setting. Mesoporous silica NPs have several advantages, such as a high surface area, tunable pore size, biocompatibility, and facile surface functionalization capabilities [ 63 ]. These characteristics enable the effective loading and controlled release of IL-10, with maximum cargo capacity and release kinetics tailored to the specific requirements of immune modulation. In addition, mesoporous silica NPs have been proven to have excellent biocompatibility and to significantly decrease unwanted reactions and cytotoxicity, which are the main issues in the case of carrier materials. Their inert nature and stability in physiological environments increases their suitability for in vivo applications, allowing targeted delivery to inflamed sites without compromising systemic safety [ 110 ].

The development of nanomaterials that regulate immune signaling pathways requires a deep understanding of materials science, pharmacology, and immunology [ 111 ]. Nanoparticles coated with programmed cell death protein 1 (PD-1) antibodies can elicit T cell responses upon interaction with tumors, thus promoting antitumor immune activity. PD-1 antibody-coated NPs play a dual role in tumor targeting and immune response regulation. Through interaction with the tumor, PD-1-antibody-coated NPs block the PD-1 receptor on T-cells, which modulates the T-cell inhibitory pathway and, consequently, acts on the immune response. Activated T-cells boost antitumor immune activity against improved tumor recognition and eradication [ 112 ]. Material science principles are critical for tailoring the physicochemical properties of nanomaterials to achieve optimal immune modulation. Surface coating, size, and composition dictate the interactions of nanoparticles with immune cells and signaling pathways. Pharmacological advances drive the rational design of nanomaterial-based therapeutics, guiding controlled release kinetics for minimal off-target effects and on-target delivery [ 113 ]. In addition, an in-depth understanding of immunological mechanisms is required for targeted immunomodulation with nanomaterials. Such a comprehensive and critical evaluation of preclinical nanotherapeutics may only be achieved with close collaboration among the research community, clinicians, and regulatory bodies so that potential off-target effects and immune sensitization are brought to light [ 114 ]. Such interdisciplinary collaboration guarantees safe and effective translation of nanomaterials.

Nanomaterials can modify immune signaling pathways, and close collaboration between researchers, clinicians, and regulatory bodies is essential to ensure rigorous preclinical evaluation to identify any potential off-target effects and sensitization of the immune system [ 115 ]. The customization of immunomodulation using nanomaterials to align with the individual profiles of patients will serve as the foundation for personalized immunotherapy. By integrating the principles of precision medicine and systemic immunology interventions, immune responses can be manipulated with high accuracy and precision [ 116 , 117 ]. The convergence of nanotechnology and immunology is a powerful tool for controlling immune responses, thereby overcoming the limitations associated with conventional disease treatments [ 118 ]. Triggered release systems offer a promising potential for revolutionizing drug delivery. These systems allow for the precise modulation of immune responses and can be targeted to specific sites of interest, either by activating or inhibiting immune reactions. This signifies the emergence of a new era in precision medicine, providing insights into the future of therapeutics [ 119 , 120 ]. The transition from laboratory discovery to clinical application requires interdisciplinary collaboration, validation of preclinical fundamentals, and committed endeavors to understanding the complexity of immune regulation [ 44 , 79 ].

The field of drug delivery has transformed into triggered release systems, as shown in Table 6 . These systems have the potential to revolutionize immunomodulatory strategies [ 77 , 121 ]. They control the release of therapeutic agents and allow for the precise modulation of immune responses. Using external or internal signals, these triggered release systems have been used in a new era of precision medicine, reshaping the future of therapeutic interventions [ 122 , 123 , 124 ].

Triggered release systems are defined by their capacity to react to external or internal signals [ 125 ]. External stimuli such as light, temperature, and magnetic fields offer precise and noninvasive triggers. Internal signals depend on the biochemical conditions of the body, including the enzymatic activity, pH, and redox potential. The integration of nanotechnology and immunology has fostered the creation of responsive nanomaterials that selectively release immunomodulatory agents upon encountering specific triggers [ 126 , 127 , 128 ].

The light-induced extraneous response involves the control of the precise amount of light without invasion. Light, as an extraneous trigger, enables precise and noninvasive control. For example, photoresponsive nanomaterials release immunoregulators under specific wavelengths of light, allowing localized calibration of the immune response [ 129 , 130 ]. This allows mild hyperthermia to exploit changes caused by the disease. Therefore, it is crucial to control the extraneous signals to achieve drug release at a specific time in the body. This is particularly important for personalizing immunomodulation and determining an approach to control extraneous signals from drugs [ 123 , 131 ].

This mode of action involves utilization of responsive internal cues through biochemical interactions within the body. Specifically, certain enzymes present in the tissue and disease microenvironment catalyze reactions to facilitate the release of drugs in a site-specific manner. This process is effectively achieved by employing nanomaterials bound to enzyme-cleavable linkages, which takes advantage of the abundance of enzymes for drug delivery [ 132 , 133 ]. The difference in pH between healthy and diseased tissues, as illustrated here, plays a crucial role in regulating drug release. Adopting such an approach would enable precise immunomodulation based on the dynamic physiological state of the body [ 134 ].

Emerging nanomaterial-based systems integrate the responsive properties with immunomodulation. Stimuli-responsive polymers, such as poly(N-isopropyl-acrylamide) (PNIPAM), undergo reversible transitions in response to temperature, enabling controlled drug release. These polymers encapsulate immunomodulatory agents and provide a temperature-triggered release profile [ 135 , 136 ]. Similarly, pH-responsive nanomaterials, such as mesoporous silica NPs and liposomes, selectively release immunomodulatory agents in specific regions upon pH variation. This demonstrates the potential of nanomaterial-based platforms for the precise modulation of the immune response modulation [ 137 , 138 ].

To fully realize this potential, it is crucial to address the challenges associated with achieving the desired release profiles, minimizing off-target effects, and ensuring optimal biocompatibility in triggered-release systems [ 139 ]. Further investigation is warranted to explore the interactions between nanomaterials and immunomodulatory agents and their impact on the immune microenvironment [ 140 ]. The integration of these materials into immunomodulatory approaches has revolutionized medicine, enabling a new era of personalized treatments.

Controlled spatiotemporal drug delivery has significant potential as an innovative approach for individual treatment with reduced toxicity [ 99 ]. This collaborative effort between disciplines has the potential to advance triggered systems, facilitate the translation of laboratory findings into clinical practice, and ultimately revolutionize therapeutic modalities [ 141 ].

For example, the improved precision offered by nanotechnology and the enhanced effectiveness of delivery, particularly in drug administration, appears to be highly promising [ 142 ]. These advancements are considered the most promising among future nanomaterials, indicating the potential and importance of essential carriers that can align with the complexities of drug delivery and immune modulation ( Table 5 ). This was further supported by an examination of immunomodulation methods using lipid-based NPs, such as liposomes, lipid NPs, and nanoemulsions [ 143 ]. The growing array of liposomes, lipid NPs, and nanoemulsions has led to the development of immunomodulatory therapeutic strategies with greater precision and efficacy [ 144 ]. Table 7 shows the various roles, features, functions, and applications of the different types of lipidic NPs that orchestrate immune responses.

2.4. Mechanisms of Action and Advantages of Lipid-Based Nanomaterials

The efficacy of lipid-based NPs in immunomodulation stems from their physical and chemical characteristics as well as their biocompatibility. These NPs can encapsulate both hydrophilic and hydrophobic immunomodulatory agents, thereby offering a wide range of therapeutic possibilities [ 150 ]. Comprised lipid bilayers interact directly with the cell membranes, promoting cellular internalization and intracellular transportation. Additionally, these carriers are biodegradable and have low toxicity, making them ideal for drug delivery and integration into the immune system [ 151 ].

Lipid-based NPs have unique benefits as vehicles for immunomodulatory drug delivery. Their natural biocompatibility reduces the risk of unintended immune reactions by preventing immune detection [ 152 , 153 ]. They also facilitate controlled and prolonged drug release, which is particularly advantageous in chronic diseases and long-term therapies [ 154 ]. These NPs can effectively deliver various immunomodulators such as cytokines, antibodies, and nucleic acids. Notably, they have demonstrated effectiveness in encapsulating siRNAs, enabling the silencing of genes related to immune disorders and showcasing their precision and potential for targeted treatments [ 155 ]. Liposomes, a subset of lipid-based NPs, are essential for delivering Toll-like receptor (TLR) agonists, which enhance immune activation and responses to vaccines [ 60 ]. Moreover, lipid-based systems have been engineered to enhance the efficacy of immune checkpoint blockade by delivering monoclonal antibodies that target inhibitory receptors. This strategy stimulates potent antitumor immune responses and advances cancer immunotherapy [ 156 ].

Lipid-based systems are versatile, spanning several therapeutic domains. In the realm of infectious diseases, liposomal formulations encapsulating antimicrobial peptides demonstrate effectiveness in targeted pathogen eradication, showing potential for enhanced treatment modalities [ 157 ]. In cancer immunotherapy, lipid-based carriers enhance the efficacy of immune checkpoint inhibitors, counteracting the immunosuppressive effects of tumors, and bolstering anticancer capabilities [ 158 ]. However, challenges persist in achieving optimal stability, managing the release kinetics, and scaling up for clinical applications [ 158 ]. Understanding the intricate interplay between lipid carriers, immune cells, and the tumor microenvironment is important for advancing this field. Engineered lipid-based systems hold promise for tailoring interventions for specific immune cell subsets, thus enabling more precise immunomodulatory strategies [ 159 ].

In summary, lipid-based NPs offer immense potential for immunomodulatory drug delivery, presenting exciting prospects for precision medicine [ 160 ]. The evolving fields of immunology and nanotechnology are poised to revolutionize therapeutic strategies through the combination of lipid-based carriers and immunomodulators [ 161 ]. Polymeric NPs are transformative elements in immunomodulatory drug delivery, and can seamlessly bridge polymer science and immunology. Biodegradable and biocompatible polymers offer a versatile platform for orchestrating immune responses with unparalleled precision [ 76 , 112 , 162 , 163 ].

2.5. Biodegradable and Biocompatible Polymers

This section presents a detailed examination of polymeric NPs in immunomodulation and highlights their potential for future therapeutic interventions ( Table 8 ). The versatility of NPs arises from the diverse range of biodegradable and biocompatible polymers that form their structures. Examples include polylactic acid (PLA), polyglycolic acid (PGA), and poly(lactic-co-glycolic acid) (PLGA). These polymers are known for their natural degradability and safety profiles, forming the basis for NPs that gradually degrade into harmless byproducts, ensuring sustained and safe immunomodulation [ 9 , 164 ]. Additionally, chitosan derived from crustacean shells exhibits unique mucoadhesive properties that are beneficial for mucosal immunomodulation [ 165 ].

Polymeric NPs possess distinct functional characteristics, depending on their design. Their size, typically ranging from 50 to 200 nm, significantly affects cellular uptake and biodistribution. Falling within this size range enables NPs to traverse the circulatory pathways while evading immune surveillance. Surface engineering methods, such as incorporating ligands or antibodies, facilitate precise targeting of therapeutic payloads to specific sites [ 166 ]. Furthermore, the controlled release of therapeutic agents from polymeric matrices ensures sustained therapeutic effects, reduces dosing frequency, and enhances patient compliance [ 167 ].

Polymeric NPs have demonstrated significant impact and transformative potential in various fields of immune modulation. In vaccine development, NPs coated with antigens and constructed from PLGA enhanced immune responses by facilitating sustained antigen presentation and activation of antigen-presenting cells [ 163 ]. During the immune checkpoint blockade, polymeric NPs armed with programmed cell death protein 1 (PD-1) antibodies induce antitumor responses by freeing PD-1-expressing T-cells and overcoming tumor-induced immunosuppression. Allergen-loaded NPs facilitate the transition from hypersensitivity to tolerance in allergy immunotherapy. For autoimmune diseases, NPs deliver disease-specific antigens or immunomodulatory agents, restoring immune balance [ 122 ]. In gene therapy, polymeric carriers deliver nucleic acids that influence the immune response at a genetic level.

Although polymeric NPs hold great promise, they face challenges, such as achieving ideal release kinetics, maintaining a uniform particle size, and managing batch-to-batch variability. Understanding cellular interactions is critical for their effective use in personalized immunomodulation strategies. Situated at the crossroads between polymer science and immunology, polymeric NPs are cutting-edge tools for delivering immunomodulatory drugs, providing unmatched precision in therapy [ 109 , 125 , 135 , 163 ]. This convergence signifies an exciting exchange between disciplines, potentially transforming the landscape of immunomodulation and personalized medicine.

2.6. Inorganic NPs for Immunomodulatory Drug Delivery

Inorganic NPs have gained significant recognition as cutting-edge carriers in immunomodulatory drug delivery. These carriers exploit the distinctive properties of materials such as gold, silica, and quantum dots [ 168 , 169 ]. The following section discusses the properties, applications, and challenges associated with inorganic NPs that facilitate precise immune modulation and targeted therapeutic interventions.

Inorganic NPs such as metals, metal oxides, and semiconductors have diverse applications. AuNPs, which are known for their plasmonic properties, are valuable in photothermal therapies and imaging, owing to their strong light absorption and scattering [ 82 ]. Silica NPs offer high biocompatibility and adjustable porosity, making them ideal for encapsulating therapeutic agents and facilitating controlled release [ 53 , 170 ]. Quantum dots and nanoscale fluorescent materials enable real-time imaging of immune cells [ 171 ]. In immunomodulation, AuNPs are used to induce localized hyperthermia under light, advancing targeted photothermal therapies for tumors and immune cells [ 82 ]. Silica nanomaterials are suitable for encapsulating immunomodulatory agents, enabling controlled release owing to their porous structure and large surface area [ 52 , 53 , 170 ].

These particles can be engineered to target specific immune cells by modifying their surface, allowing them to selectively bind to the cell surface [ 172 , 173 , 174 ]. For instance, gold NPs can be functionalized with antibodies to enhance T-cell immunity. They also carry molecules that stimulate the immune system and regulate their release [ 13 , 49 , 175 ]. In contrast, quantum dots enable the real-time tracking of immune cell behavior. Despite their potential, challenges such as achieving a uniform size distribution, maintaining stability, and addressing potential toxicity issues remain [ 171 ]. Overall, inorganic NPs represent a promising intersection of nanotechnology and immunomodulation, offering new possibilities for precision medicine [ 176 ].

3. Immunomodulatory Drug Delivery Systems in Cancer Treatment

The integration of nanotechnology and immunotherapy has significantly advanced cancer treatment, particularly for IDDSs. These systems have revolutionized the approach for combating malignancies, offering unmatched precision and efficacy, as shown in Table 7 [ 177 ]. Nanomaterial-based systems are instrumental in cancer immunotherapy because they efficiently deliver immunomodulatory agents, including immune checkpoint inhibitors, cytokines, and antigens, to counteract tumors [ 121 ]. Leveraging the distinctive characteristics of NPs, these systems surmount physiological barriers and precisely deliver therapeutic payloads to tumor sites, minimize off-target effects, and optimize anticancer responses [ 178 ].

A groundbreaking development in cancer therapy is the creation of immune checkpoint inhibitors, which empower the immune system to identify and eliminate tumor cells. NP-based systems improve the effectiveness of these inhibitors by transporting them directly into the tumor microenvironment. For instance, gold NPs coated with programmed cell death protein 1 (PD-1) antibodies efficiently hindered inhibitory signals within tumors. This action revitalizes antitumor immune responses and diminishes systemic side effects [ 179 ].

Cancer vaccines hold promise for educating and empowering the immune system against tumors. However, the challenges associated with antigen presentation and immune recognition have hindered their efficacy [ 4 , 147 , 179 , 180 ]. NP-based delivery of vaccines addresses these hurdles by encapsulating tumor antigens within lipid- or polymer-based NPs. This strategy improves antigen uptake by antigen-presenting cells, thereby eliciting strong immune responses against cancer [ 181 ].

Adoptive cell therapies, notably CAR T-cell therapy, have demonstrated remarkable efficacy against malignancies. NP-based systems can further improve these therapies by encapsulation of immunomodulatory agents. These NPs navigate the intricate immune microenvironment, fostering conditions favorable for antitumor activities and boosting the efficacy of adoptive cell therapies [ 164 , 182 ]. Despite these achievements, challenges remain, such as achieving precise control over drug release, addressing concerns regarding immunogenicity, and comprehending tumor heterogeneity. The intricate orchestration of immune responses necessitates ongoing research to elucidate the interactions between nanomaterial carriers, immune cells, and the dynamic tumor microenvironment.

The future of cancer immunotherapy holds promise for personalized intervention. Advances in genomics, proteomics, and single-cell analysis will enable the integration of nanomaterials with individual tumor immune profiles [ 124 ]. Nanomaterials represent a relatively new strategy for cancer immunotherapy, possessing multidimensional value in the targeting of tumor cells, improving the delivery of drugs at the tumor site, and modulating the tumor microenvironment. Such materials can be precisely engineered to target specific antigens on the surface of tumor cells, thereby improving the specificity and potency of immunotherapeutic agents. For instance, gold NPs have excellent photothermal properties that can achieve localized hyperthermia to kill cancer cells, thereby sparing the normal tissues. This is further applicable to drug-carrying liposomes at the nanoscale level for the delivery of chemotherapeutic agents or immunomodulators to tumor sites. By modulating the tumor microenvironment, nanomaterials can be used to enhance immune responses against cancer cells and overcome immunosuppressive barriers. These advances underscore the pivotal role of nanotechnology in reshaping cancer treatment paradigms and improving patient outcomes [ 183 ].

Nanomaterials enable the precise modulation of immune responses, offering personalized therapies that address each patient’s unique requirements. IDDSs represent a revolutionary approach to cancer treatment that supports personalized and potent immunotherapy ( Table 9 ). These systems enhance the impact of therapeutic agents by leveraging the synergy between nanotechnology and immunology, thereby leading to a new era in cancer treatment. To address these challenges, harness the potential of nanomaterials, and decipher the complexities of cancer immunity, cancer treatments have shown promise as customized, efficient, and safe therapies. This progress highlights the fusion of scientific and human resilience in cancer treatment.

4. Nanomaterial-Based Approaches for Treating Autoimmune Diseases and Chronic Inflammation

Autoimmune diseases challenge the immune system, causing chronic inflammation and tissue damage due to self-targeting dysregulated immune responses. Because the immune system is intricately involved in the pathogenesis and immune regulation of autoimmune diseases, this presents an opportunity for the most efficient nanomaterials to act as a solution for regulating the immune response by precisely targeting aberrant immune pathways and drug delivery of immunomodulatory agents in autoimmunity-affected tissues [ 184 ]. It is feasible to design nanomaterials that selectively interact with the immune cells or tissues responsible for autoimmune pathology to restore immune homeostasis and dampen adverse inflammatory responses. For example, polymeric NPs can carry either immunosuppressive drugs or antigens, allowing targeted delivery to the site of inflammation, with minimal systemic side effects. Similarly, lipid NP vesicles such as exosomes may be utilized to transport regulatory miRNAs or peptides to modulate immune cells and suppress autoimmune reactions. Evidence of nanomaterial-based therapies in both preclinical and clinical applications has shown promise and has been successful in a range of autoimmune disorders including RA, multiple sclerosis (MS), and systemic lupus erythematosus [ 185 , 186 ]. The aim is to exploit the distinct properties of nanomaterials in the development of new approaches for personalized and precision medicine in the management of autoimmune diseases, which will also improve the outcomes and quality of life of patients [ 186 ].

The combination of nanotechnology and immunology has led to innovative precision medical strategies to address autoimmune diseases and chronic inflammation. Nanomaterial-based systems, including lipids, polymers, and inorganic NPs, hold significant promise for revolutionizing the treatment of these conditions. These systems, such as liposomes, polymeric NPs, and inorganic NPs, are meticulously designed to efficiently encapsulate immunomodulatory agents [ 173 ]. By exploiting the nanoscale, these carriers can selectively accumulate at sites of inflammation, thereby diminishing the likelihood of systemic side effects, while enhancing the effectiveness of treatment. Drug delivery systems with immunomodulatory capabilities have been designed to target specific pathways and immune cell populations relevant to these diseases. For instance, in RA, NPs containing anti-inflammatory cytokines, such as IL-10, have demonstrated efficacy in reducing joint inflammation [ 13 , 45 , 72 ].

Scientists have engineered nanocarriers to ferry disease-altering medications through the blood–brain barrier (BBB) in MS, thereby mitigating inflammation within the central nervous system. Furthermore, NPs infused with anti-inflammatory substances have been used to modulate immune reactions in patients with inflammatory bowel disease (IBD) patients. The burgeoning potential of nanomaterial-driven systems in tackling autoimmune and inflammatory ailments has been bolstered by the expanding body of preclinical and clinical investigations [ 173 , 187 ]. Experimental models have demonstrated the capacity of nanocarriers to impede disease progression, limit tissue damage, and reinforce the immune equilibrium. Phase II clinical assessments have underscored the safety and effectiveness of nanomaterial-centric interventions for afflictions such as psoriasis, asthma, and lupus [ 188 ]. Despite the undeniable promise of nanomaterial-based methodologies for addressing these ailments, obstacles persist [ 189 ]. These findings underscore the potential of nanotechnology to drive a paradigm shift in approaches used to treat chronic inflammatory diseases. Although such advancements hold great promise, the translation of nanomaterial-based methodologies to clinical applications is limited [ 190 ]. It is important to emphasize the necessity of optimal biocompatibility, scalable and reproducible manufacturing processes, and acceptable long-term safety profiles. Furthermore, regulatory approval, protocol standardization, and cost-effectiveness are crucial factors that must be addressed to facilitate the widespread use of nanotherapeutics and improve outcomes in various patient populations [ 113 ]. As such, a major emphasis should be placed on strict preclinical scrutiny, careful design of clinical trials, and post-marketing surveillance to minimize risk and ensure the safe and effective deployment of nanomaterial-based interventions [ 114 ]. Further improvement in the knowledge related to pathophysiological diseases and the interaction of the host with nanomaterials will aid in designing appropriate nanotherapeutics for specific patients. These personalized medical modalities include biomarker profiling and patient stratification, which improve treatment efficacy and reduce negative effects [ 191 ]. In conclusion, nanomaterial-based approaches are promising for treating chronic inflammatory diseases. However, there remains a need to overcome overall impediments through coherent cooperation and interdisciplinary collaboration. Overcoming these challenges would, therefore, pave the way for nanotechnology in disease management for better patient outcomes.

The intricate relationship between nanomaterials, therapeutic agents, and the immune system requires a thorough understanding. Achieving targeted drug delivery, optimizing release profiles, and ensuring long-term safety require meticulous research and consideration. As the field progresses, the future of personalized management of autoimmune and inflammatory diseases relies on integrating biomarker identification, immune profiling, and tailored nanomaterial-based strategies according to disease phenotypes and individual immune signatures [ 192 ]. Nanomaterial-based approaches have revolutionized disease management by combining nanotechnology precision with immunological complexity. These strategies finely tune immune responses and have been proven to be accurate and effective in treating autoimmune diseases and chronic inflammation, thus marking the beginning of a new era of immune modulation [ 193 ]. With the emergence of nanomaterial-based IDDSs in precision medicine, meticulous safety considerations are imperative. The intricate interaction between nanomaterials and immune responses requires thorough evaluation to ensure the safety and efficacy of these interventions [ 194 ]. The advancement of safe immunomodulatory drug delivery systems relies on the biocompatibility of the nanomaterials. Achieving this requires NPs to navigate physiological barriers, interact with immune cells, and regulate drug dispersal, while minimizing potential adverse effects [ 195 ]. When assessing the potential toxicity of NPs, critical factors such as size, surface chemistry, charge, and composition must be carefully considered because these factors significantly affect cellular uptake, immune response, and systemic distribution [ 196 ].

Comprehensive safety assessments are crucial for the successful translation of nanomaterial-based systems from the laboratory to clinical settings. In vitro studies are essential for understanding cellular reactions and cytotoxicity as they provide initial data on the compatibility of nanomaterials with immune cells [ 197 ]. Animal models have been pivotal in evaluating the toxicological effects of various NPs, underscoring the need for improved physicochemical assays to accurately assess exposure risks and predict their behavior and therapeutic potential in vivo [ 198 ]. Animal models have been particularly useful for studying the toxic effects of dendrimers, silver NPs, gold NPs, and carbon nanotubes [ 199 ].

Enhancing the safety of nanomaterial-based IDDSs requires a multi-faceted approach. This involves designing NPs with tailored physicochemical characteristics to minimize immune recognition and cellular uptake [ 200 ]. Surface modifications using biocompatible polymers or stealth coatings can effectively reduce the opsonization and immune clearance. The selection of biodegradable materials ensures that NPs are metabolized into harmless byproducts, thereby minimizing the potential long-term effects [ 201 ].

Personalized safety assessments are essential for developing nanomaterial-based immunomodulatory systems. Recognizing unique variations in immune responses, genetic profiles, and underlying health conditions emphasizes the need for tailored intervention [ 202 ]. Advanced techniques, such as organ-on-a-chip models and patient-derived cell cultures, provide sophisticated platforms for personalized safety assessment and refine therapeutic strategies to achieve optimal safety and effectiveness [ 203 ].

The transition from research exploration to the clinical application of nanomaterial-based systems requires adherence to comprehensive regulatory guidelines and standardized procedures. Regulatory bodies scrutinize safety data, necessitating robust evidence of biocompatibility, pharmacokinetics, and toxicity, as summarized in Table 10 . Standardized protocols governing nanomaterial synthesis, characterization, and safety assessment promote consistency in reporting, transparency enhancement, and credibility across studies [ 85 , 197 ]. Innovations in nanomaterial-based IDDSs must prioritize safety and draw lessons from past experiences in future research. Collaboration among scientists, clinicians, and regulatory authorities is key to balancing scientific advancements with patient safety. Nanomaterials offer promising potential for therapeutic advancements, ensuring patient safety through comprehensive evaluation, personalized methodologies, and regulatory adherence [ 200 ]. Navigating the complexities of nanotechnology demonstrates a commitment to establishing a future in which innovative and patient-centered immunomodulatory treatments can become a reality.

5. Conclusions and Future Directions

In medicine, tailored and precise techniques are gaining traction with the combination of nanotechnology and immunology, resulting in the development of IDDSs. This review focuses on these systems and investigates their transformational potential in immunotherapy and disease treatment. We summarize the major discoveries, evaluate the possibilities of nanomaterial-based systems, and provide insights into future research.

IDDSs that use nanomaterials provide promising opportunities to modify the immune responses to various illnesses. By combining nanotechnology with immunology, these approaches allow for targeted administration of immunomodulatory drugs to specific immune cells and inflamed areas. This study focuses on how nanomaterials can improve immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies, resulting in more effective treatments tailored to specific patients. However, further refinement are required. Optimization of NP properties, surface qualities, and targeting abilities is critical for improving their interactions with immune cells.

The use of personalized therapies based on patient-specific immune markers, coupled with the integration of artificial intelligence into material design, has the potential to expedite the identification of promising candidates for clinical application. The introduction of nanomaterial-based systems into clinical practice necessitates careful management of regulatory complications, safety issues, and scalability. Achieving a balance between scientific innovation and regulatory compliance is therefore critical. Thorough safety reviews, toxicity assessments, and rigorous clinical trials are required to ensure patient safety and therapeutic efficacy. Acceleration of the clinical translation of nanomaterial-based immunotherapies will require collaborative approaches, early engagement with regulatory bodies, optimized trial protocols, engagement with patients, increased investment, international cooperation, risk management, strategic partnerships, and real-world evidence.

Advances in nanotechnology promise to improve drug delivery to specific immune cells, thereby extending its application in immunomodulation. Personalized therapy, which is driven by patients’ immunological profiles and AI, enables rapid clinical implementation. Collaboration between scientists and clinicians has accelerated translation efforts. Tailored regulations are critical for broadening therapeutic applications of nanomaterial-based immunomodulation. Exploring molecular-level immune responses requires precise manipulation using sophisticated nanomaterial design. Overcoming obstacles, such as scalability, consistency, and safety, is critical for effective clinical translation. The focus on patient-centered outcomes prioritizes treatment effectiveness, quality of life, and adherence to nanomaterial-based therapeutics. The anticipated worldwide collaboration will accelerate advances in immunomodulation and medication delivery, thereby boosting the creativity and efficacy of treatment approaches. Nanomaterial-based immunotherapy has shown promise in preclinical research and has moved into early clinical trials, with ongoing efforts focused on targeted delivery and controlled release to specific cells. However, this strategy is not widely applied in clinical practice yet, and further development is required to overcome current challenges.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

A.A.A.A., conceptualization review writing, reviewing, and revising; M.A.O., O.G., M.E.-T., V.M., Y.M., S.K., S.S.P., S.S.H., D.N., K.L., A.H.-J., Á.S.-A., E.M.R., V.N.U. and M.M.T., review data gathering, writing, reviewing, and revising. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

No data were generated during the preparation of this manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Alshawwa S.Z. Kassem A.A. Farid R.M. Mostafa S.K. Labib G.S. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence Pharmaceutics 2022 14 883 10.3390/pharmaceutics14040883 35456717 PMC9026217

2. Aljabali A.A. Obeid M.A. Bashatwah R.M. Serrano-Aroca Á. Mishra V. Mishra Y. El-Tanani M. Hromić-Jahjefendić A. Kapoor D.N. Goyal R. Nanomaterials and Their Impact on the Immune System Int. J. Mol. Sci. 2023 24 8 10.3390/ijms24032008 36768330 PMC9917130

3. Liu Y. Guo J. Huang L. Modulation of tumor microenvironment for immunotherapy: Focus on nanomaterial-based strategies Theranostics 2020 10 3099 3117 10.7150/thno.42998 32194857 PMC7053194

4. Dupoiron D. Duarte R. Carvajal G. Aubrun F. Eldabe S. Rationale and Recent Advances in Targeted Drug Delivery for Cancer Pain: Is It Time to Change the Paradigm? Pain Physician 2022 25 E414 E425 35652767

5. Shen Q. Du Y. A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis Int. J. Pharm. 2023 635 122698 10.1016/j.ijpharm.2023.122698 36754181

6. Quarterman J.C. Geary S.M. Salem A.K. Evolution of drug-eluting biomedical implants for sustained drug delivery Eur. J. Pharm. Biopharm. 2021 159 21 35 10.1016/j.ejpb.2020.12.005 33338604 PMC7856224

7. Fayzullin A. Bakulina A. Mikaelyan K. Shekhter A. Guller A. Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape Bioengineering 2021 8 205 10.3390/bioengineering8120205 34940358 PMC8698517

8. Dash A.K. Cudworth G.C. 2nd Therapeutic applications of implantable drug delivery systems J. Pharm. Toxicol. Methods 1998 40 1 12 10.1016/s1056-8719(98)00027-6 9920528

9. Bhardwaj H. Jangde R.K. Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications Next Nanotechnol. 2023 2 100013 10.1016/j.nxnano.2023.100013

10. Mulhern O. Harrington B. Bowie A.G. Modulation of innate immune signalling pathways by viral proteins Adv. Exp. Med. Biol. 2009 666 49 63 10.1007/978-1-4419-1601-3_4 20054974

11. Han S. Quach T. Hu L. Wahab A. Charman W.N. Stella V.J. Trevaskis N.L. Simpson J.S. Porter C.J.H. Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies J. Control. Release 2014 177 1 10 10.1016/j.jconrel.2013.12.031 24398334

12. Manzari M.T. Shamay Y. Kiguchi H. Rosen N. Scaltriti M. Heller D.A. Targeted drug delivery strategies for precision medicines Nat. Rev. Mater. 2021 6 351 370 10.1038/s41578-020-00269-6 34950512 PMC8691416

13. Panigrahy D. Gilligan M.M. Huang S. Gartung A. Cortés-Puch I. Sime P.J. Phipps R.P. Serhan C.N. Hammock B.D. Inflammation resolution: A dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020 39 337 340 10.1007/s10555-020-09889-4 32385712 PMC7207990

14. Cazzamalli S. Corso A.D. Neri D. Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments Chimia 2017 71 712 715 10.2533/chimia.2017.712 29070415 PMC5844459

15. Sathish J.G. Sethu S. Bielsky M.-C. de Haan L. French N.S. Govindappa K. Green J. Griffiths C.E.M. Holgate S. Jones D. Challenges and approaches for the development of safer immunomodulatory biologics Nat. Rev. Drug Discov. 2013 12 306 324 10.1038/nrd3974 23535934 PMC7097261

16. Desai A.K. Li C. Rosenberg A.S. Kishnani P.S. Immunological challenges and approaches to immunomodulation in Pompe disease: A literature review Ann. Transl. Med. 2019 7 285 10.21037/atm.2019.05.27 31392197 PMC6642943

17. Miller W.G. Greenberg N. Harmonization and Standardization: Where Are We Now? J. Appl. Lab. Med. 2021 6 510 521 10.1093/jalm/jfaa189 33241270

18. Sushnitha M. Evangelopoulos M. Tasciotti E. Taraballi F. Cell membrane-based biomimetic nanoparticles and the immune system: Immunomodulatory interactions to therapeutic applications Front. Bioeng. Biotechnol. 2020 8 627 10.3389/fbioe.2020.00627 32626700 PMC7311577

19. Yang C. Blum N.T. Lin J. Qu J. Huang P. Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy Sci. Bull. 2020 65 1489 1504 10.1016/j.scib.2020.04.012 36747406

20. Jindal A. Sarkar S. Alam A. Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics Front. Chem. 2021 9 629635 10.3389/fchem.2021.629635 33708759 PMC7940769

21. Alagarsamy K.N. Mathan S. Yan W. Rafieerad A. Sekaran S. Manego H. Dhingra S. Carbon Nanomaterials for Cardiovascular Theranostics: Promises and Challenges Bioact. Mater. 2021 6 2261 2280 10.1016/j.bioactmat.2020.12.030 33553814 PMC7829079

22. Seth A. Gholami Derami H. Gupta P. Wang Z. Rathi P. Gupta R. Cao T. Morrissey J.J. Singamaneni S. Polydopamine–mesoporous silica core–shell nanoparticles for combined photothermal immunotherapy ACS Appl. Mater. Interfaces 2020 12 42499 42510 10.1021/acsami.0c10781 32838525 PMC7942218

23. Fontana F. Figueiredo P. Bauleth-Ramos T. Correia A. Santos H.A. Immunostimulation and Immunosuppression: Nanotechnology on the Brink Small Methods 2018 2 1700347 10.1002/smtd.201700347

24. Ding F. Zhang S. Chen Q. Feng H. Ge Z. Zuo X. Fan C. Li Q. Xia Q. Immunomodulation With Nucleic Acid Nanodevices Small 2023 19 2206228 10.1002/smll.202206228 36599642

25. Zhu X. Li S. Nanomaterials in tumor immunotherapy: New strategies and challenges Mol. Cancer 2023 22 94 10.1186/s12943-023-01797-9 37312116 PMC10262535

26. Liu Q. Duo Y. Fu J. Qiu M. Sun Z. Adah D. Kang J. Xie Z. Fan T. Bao S. Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy Nano Today 2021 36 101023 10.1016/j.nantod.2020.101023

27. Niculescu A.G. Grumezescu A.M. Novel Tumor-Targeting Nanoparticles for Cancer Treatment-A Review Int. J. Mol. Sci. 2022 23 5253 10.3390/ijms23095253 35563645 PMC9101878

28. Zhu R. Zhang F. Peng Y. Xie T. Wang Y. Lan Y. Current Progress in Cancer Treatment Using Nanomaterials Front. Oncol. 2022 12 930125 10.3389/fonc.2022.930125 35912195 PMC9330335

29. Mansoori B. Mohammadi A. Abedi-Gaballu F. Abbaspour S. Ghasabi M. Yekta R. Shirjang S. Dehghan G. Hamblin M.R. Baradaran B. Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells J. Cell Physiol. 2020 235 6817 6830 10.1002/jcp.29576 31989649 PMC7384933

30. Rad L.M. Arellano G. Podojil J.R. O’Konek J.J. Shea L.D. Miller S.D. Engineering nanoparticle therapeutics for food allergy J. Allergy Clin. Immunol. 2024 153 549 559 10.1016/j.jaci.2023.10.013 37926124 PMC10939913

31. Akdis M. Akdis C.A. Mechanisms of allergen-specific immunotherapy J. Allergy Clin. Immunol. 2007 119 780 789 10.1016/j.jaci.2007.01.022 17321578

32. Zhu Y.-S. Tang K. Lv J. Peptide–drug conjugate-based novel molecular drug delivery system in cancer Trends Pharmacol. Sci. 2021 42 857 869 10.1016/j.tips.2021.07.001 34334251

33. Gocheva G. Ivanova A. A look at receptor–ligand pairs for active-targeting drug delivery from crystallographic and molecular dynamics perspectives Mol. Pharm. 2019 16 3293 3321 10.1021/acs.molpharmaceut.9b00250 31274322

34. Sujka M. Pankiewicz U. Kowalski R. Nowosad K. Noszczyk-Nowak A. Porous starch and its application in drug delivery systems Polim. W Med. 2018 48 25 29 10.17219/pim/99799 30657655

35. Pacardo D.B. Ligler F.S. Gu Z. Programmable nanomedicine: Synergistic and sequential drug delivery systems Nanoscale 2015 7 3381 3391 10.1039/C4NR07677J 25631684

36. Demetzos C. Pippa N. Advanced drug delivery nanosystems (aDDnSs): A mini-review Drug Deliv. 2014 21 250 257 10.3109/10717544.2013.844745 24134707

37. Mobeen H. Safdar M. Fatima A. Afzal S. Zaman H. Mehdi Z. Emerging applications of nanotechnology in context to immunology: A comprehensive review Front. Bioeng. Biotechnol. 2022 10 1024871 10.3389/fbioe.2022.1024871 36619389 PMC9815620

38. Chuang S.T. Conklin B. Stein J.B. Pan G. Lee K.-B. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications Nano Converg. 2022 9 19 10.1186/s40580-022-00310-0 35482149 PMC9047473

39. Mendes B.B. Conniot J. Avital A. Yao D. Jiang X. Zhou X. Sharf-Pauker N. Xiao Y. Adir O. Liang H. Nanodelivery of nucleic acids Nat. Rev. Methods Prim. 2022 2 24 10.1038/s43586-022-00104-y PMC9038125 35480987

40. Zhu L. Yu X. Cao T. Deng H. Tang X. Lin Q. Zhou Q. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis Acta Pharm. Sin. B 2023 13 2464 2482 10.1016/j.apsb.2023.03.004 37425034 PMC10326251

41. Cruz L.J. Tacken P.J. Rueda F. Domingo J.C. Albericio F. Figdor C.G. Targeting nanoparticles to dendritic cells for immunotherapy Methods Enzym. 2012 509 143 163 10.1016/b978-0-12-391858-1.00008-3 22568905

42. Jia J. Zhang Y. Xin Y. Jiang C. Yan B. Zhai S. Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy Front. Oncol. 2018 8 404 10.3389/fonc.2018.00404 30319969 PMC6167641

43. Simon J. Fichter M. Kuhn G. Brückner M. Kappel C. Schunke J. Klaus T. Grabbe S. Landfester K. Mailänder V. Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers Nano Today 2022 43 101375 10.1016/j.nantod.2022.101375

44. Chen S. Saeed A.F.U.H. Liu Q. Jiang Q. Xu H. Xiao G.G. Rao L. Duo Y. Macrophages in immunoregulation and therapeutics Signal Transduct. Target. Ther. 2023 8 207 10.1038/s41392-023-01452-1 37211559 PMC10200802

45. Hu G. Guo M. Xu J. Wu F. Fan J. Huang Q. Yang G. Lv Z. Wang X. Jin Y. Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation Front. Immunol. 2019 10 1998 10.3389/fimmu.2019.01998 31497026 PMC6712945

46. Lôbo G. Paiva K.L.R. Silva A.L.G. Simões M.M. Radicchi M.A. Báo S.N. Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy Pharmaceutics 2021 13 1167 10.3390/pharmaceutics13081167 34452128 PMC8399799

47. Majumder J. Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery Expert Opin. Drug Deliv. 2021 18 205 227 10.1080/17425247.2021.1828339 32969740 PMC7904578

48. Elzoghby A.O. Abdelmoneem M.A. Hassanin I.A. Abd Elwakil M.M. Elnaggar M.A. Mokhtar S. Fang J.-Y. Elkhodairy K.A. Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand Biomaterials 2020 263 120355 32932142 10.1016/j.biomaterials.2020.120355 PMC7480805

49. Heimall J. The Adaptive Cellular Immune Response: T Cells and Cytokines. UpToDate 2022 Available online: https://www.uptodate.com/contents/the-adaptive-cellular-immune-response-t-cells-and-cytokines (accessed on 15 May 2024)

50. Sun L. Su Y. Jiao A. Wang X. Zhang B. T cells in health and disease Signal Transduct. Target. Ther. 2023 8 235 10.1038/s41392-023-01471-y 37332039 PMC10277291

51. Chen L. Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 2013 13 227 242 10.1038/nri3405 23470321 PMC3786574

52. Gupta J. Quadros M. Momin M. Mesoporous silica nanoparticles: Synthesis and multifaceted functionalization for controlled drug delivery J. Drug Deliv. Sci. Technol. 2023 81 104305 10.1016/j.jddst.2023.104305

53. Noureddine A. Maestas-Olguin A. Tang L. Corman-Hijar J.I. Olewine M. Krawchuck J.A. Tsala Ebode J. Edeh C. Dang C. Negrete O.A. Future of Mesoporous Silica Nanoparticles in Nanomedicine: Protocol for Reproducible Synthesis, Characterization, Lipid Coating, and Loading of Therapeutics (Chemotherapeutic, Proteins, siRNA and mRNA) ACS Nano 2023 17 16308 16325 10.1021/acsnano.3c07621 37643407

54. Eloy J.O. Petrilli R. Trevizan L.N.F. Chorilli M. Immunoliposomes: A review on functionalization strategies and targets for drug delivery Colloids Surf. B Biointerfaces 2017 159 454 467 10.1016/j.colsurfb.2017.07.085 28837895

55. Faham A. Altin J.G. Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity Int. J. Cancer 2011 129 1391 1403 10.1002/ijc.25810 21128234

56. Hama S. Sakai M. Itakura S. Majima E. Kogure K. Rapid modification of antibodies on the surface of liposomes composed of high-affinity protein A-conjugated phospholipid for selective drug delivery Biochem. Biophys. Rep. 2021 27 101067 10.1016/j.bbrep.2021.101067 34258398 PMC8260867

57. Ohradanova-Repic A. Nogueira E. Hartl I. Gomes A.C. Preto A. Steinhuber E. Mühlgrabner V. Repic M. Kuttke M. Zwirzitz A. Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells Nanomed. Nanotechnol. Biol. Med. 2018 14 123 130 10.1016/j.nano.2017.09.003 28939491

58. Millozzi F. Papait A. Bouché M. Parolini O. Palacios D. Nano-Immunomodulation: A New Strategy for Skeletal Muscle Diseases and Aging? Int. J. Mol. Sci. 2023 24 1175 10.3390/ijms24021175 36674691 PMC9862642

59. Cifuentes-Rius A. Desai A. Yuen D. Johnston A.P.R. Voelcker N.H. Inducing immune tolerance with dendritic cell-targeting nanomedicines Nat. Nanotechnol. 2021 16 37 46 10.1038/s41565-020-00810-2 33349685

60. Yousefpour P. Ni K. Irvine D.J. Targeted modulation of immune cells and tissues using engineered biomaterials Nat. Rev. Bioeng. 2023 1 107 124 10.1038/s44222-022-00016-2 37772035 PMC10538251

61. Wang D.-R. Wu X.-L. Sun Y.-L. Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response Signal Transduct. Target. Ther. 2022 7 331 10.1038/s41392-022-01136-2 36123348 PMC9485144

62. Immune discovery aplenty at twenty Nat. Rev. Immunol. 2021 21 613 10.1038/s41577-021-00623-x 34580466

63. Tang F. Li L. Chen D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery Adv. Mater. 2012 24 1504 1534 10.1002/adma.201104763 22378538

64. Villani A.C. Sarkizova S. Hacohen N. Systems Immunology: Learning the Rules of the Immune System Annu. Rev. Immunol. 2018 36 813 842 10.1146/annurev-immunol-042617-053035 29677477 PMC6597491

65. Brameshuber M. Klotzsch E. Ponjavic A. Sezgin E. Understanding immune signaling using advanced imaging techniques Biochem. Soc. Trans. 2022 50 853 866 10.1042/bst20210479 35343569 PMC9162467

66. Bonaguro L. Schulte-Schrepping J. Ulas T. Aschenbrenner A.C. Beyer M. Schultze J.L. A guide to systems-level immunomics Nat. Immunol. 2022 23 1412 1423 10.1038/s41590-022-01309-9 36138185

67. Yuba E. Fukaya Y. Yanagihara S. Kasho N. Harada A. Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery Pharmaceutics 2020 12 754 10.3390/pharmaceutics12080754 32796567 PMC7465930

68. Wang F. Xiao W. Elbahnasawy M.A. Bao X. Zheng Q. Gong L. Zhou Y. Yang S. Fang A. Farag M.M.S. Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes Front. Pharm. 2018 9 980 10.3389/fphar.2018.00980 PMC6134263 30233368

69. Liu J. Xavy S. Mihardja S. Chen S. Sompalli K. Feng D. Choi T. Agoram B. Majeti R. Weissman I.L. Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy JCI Insight 2020 5 e134728 10.1172/jci.insight.134728 32427583 PMC7406266

70. Yu W.-B. Ye Z.-H. Chen X. Shi J.-J. Lu J.-J. The development of small-molecule inhibitors targeting CD47 Drug Discov. Today 2021 26 561 568 10.1016/j.drudis.2020.11.003 33197622

71. Hou X. Zaks T. Langer R. Dong Y. Lipid nanoparticles for mRNA delivery Nat. Rev. Mater. 2021 6 1078 1094 10.1038/s41578-021-00358-0 34394960 PMC8353930

72. Kraynak C.A. Huang W. Bender E.C. Wang J.-L. Hanafy M.S. Cui Z. Suggs L.J. Apoptotic body-inspired nanoparticles target macrophages at sites of inflammation to support an anti-inflammatory phenotype shift Int. J. Pharm. 2022 618 121634 10.1016/j.ijpharm.2022.121634 35247497 PMC9007911

73. Wu Y. Wan S. Yang S. Hu H. Zhang C. Lai J. Zhou J. Chen W. Tang X. Luo J. Macrophage cell membrane-based nanoparticles: A new promising biomimetic platform for targeted delivery and treatment J. Nanobiotechnology 2022 20 542 10.1186/s12951-022-01746-6 36575429 PMC9794113

74. Cai D. Gao W. Li Z. Zhang Y. Xiao L. Xiao Y. Current Development of Nano-Drug Delivery to Target Macrophages Biomedicines 2022 10 1203 10.3390/biomedicines10051203 35625939 PMC9139084

75. Chaintreuil P. Kerreneur E. Bourgoin M. Savy C. Favreau C. Robert G. Jacquel A. Auberger P. The generation, activation, and polarization of monocyte-derived macrophages in human malignancies Front. Immunol. 2023 14 1178337 10.3389/fimmu.2023.1178337 37143666 PMC10151765

76. Pinto I.S. Cordeiro R.A. Faneca H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy J. Control. Release 2023 353 196 215 10.1016/j.jconrel.2022.11.038 36423871

77. Est-Witte S.E. Livingston N.K. Omotoso M.O. Green J.J. Schneck J.P. Nanoparticles for generating antigen-specific T cells for immunotherapy Semin. Immunol. 2021 56 101541 10.1016/j.smim.2021.101541 34922816 PMC8900015

78. Konkel J.E. Zhang D. Zanvit P. Chia C. Zangarle-Murray T. Jin W. Wang S. Chen W. Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses Immunity 2017 46 660 674 10.1016/j.immuni.2017.03.015 28423340 PMC12230991

79. Polanczyk M.J. Walker E. Haley D. Guerrouahen B.S. Akporiaye E.T. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4(+)CD25(+)Foxp3(+) and CD4(+)CD25(-)Foxp3(+) T cells J. Transl. Med. 2019 17 219 10.1186/s12967-019-1967-3 31288845 PMC6617864

80. Delobel P. Ginter B. Rubio E. Balabanian K. Lazennec G. CXCR2 intrinsically drives the maturation and function of neutrophils in mice Front. Immunol. 2022 13 1005551 10.3389/fimmu.2022.1005551 36311783 PMC9606682

81. Metzemaekers M. Gouwy M. Proost P. Neutrophil chemoattractant receptors in health and disease: Double-edged swords Cell. Mol. Immunol. 2020 17 433 450 10.1038/s41423-020-0412-0 32238918 PMC7192912

82. Shamalov K. Meir R. Motiei M. Popovtzer R. Cohen C.J. Noninvasive Tracking of Natural Killer Cells Using Gold Nanoparticles ACS Omega 2021 6 28507 28514 10.1021/acsomega.1c02143 34746546 PMC8567284

83. Murugan D. Murugesan V. Panchapakesan B. Rangasamy L. Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy Cancers 2022 14 5438 10.3390/cancers14215438 36358857 PMC9653801

84. Kläsener K. Jellusova J. Andrieux G. Salzer U. Böhler C. Steiner S.N. Albinus J.B. Cavallari M. Süß B. Voll R.E. CD20 as a gatekeeper of the resting state of human B cells Proc. Natl. Acad. Sci. USA 2021 118 e2021342118 10.1073/pnas.2021342118 33563755 PMC7896350

85. Luo C. Wu G. Huang X. Ma Y. Zhang Y. Song Q. Xie M. Sun Y. Huang Y. Huang Z. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: A systematic review and meta-analysis Sci. Rep. 2021 11 3255 10.1038/s41598-021-82841-w 33547368 PMC7864901

86. Bevins N.J. Okamura R. Montesion M. Adashek J.J. Goodman A.M. Kurzrock R. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy J. Immunother. Precis. Oncol. 2022 5 90 97 10.36401/jipo-22-9 36483582 PMC9714418

87. Nagasaki J. Inozume T. Sax N. Ariyasu R. Ishikawa M. Yamashita K. Kawazu M. Ueno T. Irie T. Tanji E. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes Cell Rep. 2022 38 110331 10.1016/j.celrep.2022.110331 35108529

88. Kasturi S.P. Skountzou I. Albrecht R.A. Koutsonanos D. Hua T. Nakaya H.I. Ravindran R. Stewart S. Alam M. Kwissa M. Programming the magnitude and persistence of antibody responses with innate immunity Nature 2011 470 543 547 10.1038/nature09737 21350488 PMC3057367

89. Napolitani G. Rinaldi A. Bertoni F. Sallusto F. Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells Nat. Immunol. 2005 6 769 776 10.1038/ni1223 15995707 PMC3760217

90. Gaur M. Misra C. Yadav A.B. Swaroop S. Maolmhuaidh F. Bechelany M. Barhoum A. Biomedical Applications of Carbon Nanomaterials: Fullerenes, Quantum Dots, Nanotubes, Nanofibers, and Graphene Materials 2021 14 5978 10.3390/ma14205978 34683568 PMC8538389

91. Song E. Han W. Li C. Cheng D. Li L. Liu L. Zhu G. Song Y. Tan W. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery ACS Appl. Mater. Interfaces 2014 6 11882 11890 10.1021/am502423r 25000539

92. Kim Y.E. Kim J. ROS-scavenging therapeutic hydrogels for modulation of the inflammatory response ACS Appl. Mater. Interfaces 2021 14 23002 23021 10.1021/acsami.1c18261 34962774

93. Chao Y. Karmali P.P. Mukthavaram R. Kesari S. Kouznetsova V.L. Tsigelny I.F. Simberg D. Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI ACS Nano 2013 7 4289 4298 10.1021/nn400769e 23614696

94. Zhang Y. Zhang Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Cell. Mol. Immunol. 2020 17 807 821 10.1038/s41423-020-0488-6 32612154 PMC7395159

95. Kumar A.R. Devan A.R. Nair B. Vinod B.S. Nath L.R. Harnessing the immune system against cancer: Current immunotherapy approaches and therapeutic targets Mol. Biol. Rep. 2021 48 8075 8095 10.1007/s11033-021-06752-9 34671902 PMC8605995

96. Pai S.G. Carneiro B.A. Mota J.M. Costa R. Leite C.A. Barroso-Sousa R. Kaplan J.B. Chae Y.K. Giles F.J. Wnt/beta-catenin pathway: Modulating anticancer immune response J. Hematol. Oncol. 2017 10 101 10.1186/s13045-017-0471-6 28476164 PMC5420131

97. Lin G. Wang J. Yang Y.-G. Zhang Y. Sun T. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance Front. Bioeng. Biotechnol. 2023 11 10.3389/fbioe.2023.1242126 37877041 PMC10593475

98. Kanoh H. Iwashita S. Kuraishi T. Goto A. Fuse N. Ueno H. Nimura M. Oyama T. Tang C. Watanabe R. cGMP signaling pathway that modulates NF-κB activation in innate immune responses iScience 2021 24 103473 10.1016/j.isci.2021.103473 34988396 PMC8710550

99. Strzelec M. Detka J. Mieszczak P. Sobocińska M.K. Majka M. Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system Front. Immunol. 2023 14 1127704 10.3389/fimmu.2023.1127704 36969193 PMC10033545

100. Singh R. Srinivas S.P. Kumawat M. Daima H.K. Ligand-based surface engineering of nanomaterials: Trends, challenges, and biomedical perspectives OpenNano 2024 15 100194 10.1016/j.onano.2023.100194

101. Khan A. Dias F. Neekhra S. Singh B. Srivastava R. Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics Front. Chem. 2020 8 631351 10.3389/fchem.2020.631351 33585406 PMC7878384

102. Zheng C. Wang Q. Wang Y. Zhao X. Gao K. Liu Q. Zhao Y. Zhang Z. Zheng Y. Cao J. In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice Adv. Mater. 2019 31 e1902542 10.1002/adma.201902542 31183900

103. Jiang L. Sun Q. The Expression Profile of Human Peripheral Blood Mononuclear Cell miRNA Is Altered by Antibody-Dependent Enhancement of Infection with Dengue Virus Serotype 3 Virol. J. 2018 15 50 10.1186/s12985-018-0963-1 29566761 PMC5863830

104. Zhang P. Meng J. Li Y. Yang C. Hou Y. Tang W. McHugh K.J. Jing L. Nanotechnology-Enhanced Immunotherapy for Metastatic Cancer Innovation 2021 2 100174 10.1016/j.xinn.2021.100174 34766099 PMC8571799

105. Singh R. Kumawat M. Gogoi H. Madhyastha H. Lichtfouse E. Daima H.K. Engineered Nanomaterials for Immunomodulation: A Review Acs Appl. Bio Mater. 2024 7 727 751 10.1021/acsabm.3c00940 38166376

106. Chen Y. Gao D.Y. Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies Adv. Drug Deliv. Rev. 2015 81 128 141 10.1016/j.addr.2014.05.009 24859533 PMC5009470

107. Nano-enabled immunomodulation Nat. Nanotechnol. 2021 16 1 10.1038/s41565-020-00842-8 33437037

108. Dararatana N. Seidi F. Hamel J. Crespy D. Controlling release kinetics of pH-responsive polymer nanoparticles Polym. Chem. 2020 11 1752 1762 10.1039/C9PY01946D

109. Takemoto H. Nishiyama N. Construction of nanomaterials based on pH-responsive polymers for effective tumor delivery Polym. J. 2021 53 1353 1360 10.1038/s41428-021-00542-7

110. Xu B. Li S. Shi R. Liu H. Multifunctional mesoporous silica nanoparticles for biomedical applications Signal Transduct. Target. Ther. 2023 8 435 10.1038/s41392-023-01654-7 37996406 PMC10667354

111. Khatun S. Putta C.L. Hak A. Rengan A.K. Immunomodulatory nanosystems: An emerging strategy to combat viral infections Biomater. Biosyst. 2023 9 100073 10.1016/j.bbiosy.2023.100073 36967725 PMC10036237

112. Bochicchio S. Lamberti G. Barba A.A. Polymer-Lipid Pharmaceutical Nanocarriers: Innovations by New Formulations and Production Technologies Pharmaceutics 2021 13 198 10.3390/pharmaceutics13020198 33540659 PMC7913085

113. Ju Y. Kelly H.G. Dagley L.F. Reynaldi A. Schlub T.E. Spall S.K. Bell C.A. Cui J. Mitchell A.J. Lin Z. Person-specific biomolecular coronas modulate nanoparticle interactions with immune cells in human blood ACS Nano 2020 14 15723 15737 10.1021/acsnano.0c06679 33112593

114. Sofias A.M. Andreassen T. Hak S. Nanoparticle ligand-decoration procedures affect in vivo interactions with immune cells Mol. Pharm. 2018 15 5754 5761 10.1021/acs.molpharmaceut.8b00908 30376341

115. Toy R. Roy K. Engineering nanoparticles to overcome barriers to immunotherapy Bioeng. Transl. Med. 2016 1 47 62 10.1002/btm2.10005 29313006 PMC5689503

116. Liu L. Chen J. Zhang H. Ye J. Moore C. Lu C. Fang Y. Fu Y.-X. Li B. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity Nat. Cancer 2022 3 437 452 10.1038/s43018-022-00352-7 35393580 PMC9050907

117. Kubli S.P. Berger T. Araujo D.V. Siu L.L. Mak T.W. Beyond immune checkpoint blockade: Emerging immunological strategies Nat. Rev. Drug Discov. 2021 20 899 919 10.1038/s41573-021-00155-y 33686237

118. Pognan F. Beilmann M. Boonen H.C.M. Czich A. Dear G. Hewitt P. Mow T. Oinonen T. Roth A. Steger-Hartmann T. The evolving role of investigative toxicology in the pharmaceutical industry Nat. Rev. Drug Discov. 2023 22 317 335 10.1038/s41573-022-00633-x 36781957 PMC9924869

119. Deng Z. Wang N. Ai F. Wang Z. Zhu G. Nanomaterial-mediated platinum drug-based combinatorial cancer therapy VIEW 2021 2 20200030 10.1002/VIW.20200030

120. Babbitt C.W. Moore E.A. Sustainable nanomaterials by design Nat. Nanotechnol. 2018 13 621 623 10.1038/s41565-018-0235-7 30082803

121. Jiang Z. Zhang W. Zhang J. Liu T. Xing J. Zhang H. Tang D. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy Int. J. Nanomed. 2022 17 4677 4696 10.2147/ijn.S376216 PMC9541303 36211025

122. Longo A. Longo V. Colombo P. Nanoparticles in allergen immunotherapy Curr. Opin. Allergy Clin. Immunol. 2021 21 576 582 10.1097/aci.0000000000000782 34419966

123. Ma X. Liang X. Li Y. Feng Q. Cheng K. Ma N. Zhu F. Guo X. Yue Y. Liu G. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field Nat. Commun. 2023 14 1606 10.1038/s41467-023-37225-1 36959204 PMC10036336

124. Murciano-Goroff Y.R. Warner A.B. Wolchok J.D. The future of cancer immunotherapy: Microenvironment-targeting combinations Cell Res. 2020 30 507 519 10.1038/s41422-020-0337-2 32467593 PMC7264181

125. Wells C.M. Harris M. Choi L. Murali V.P. Guerra F.D. Jennings J.A. Stimuli-Responsive Drug Release from Smart Polymers J. Funct. Biomater. 2019 10 34 10.3390/jfb10030034 31370252 PMC6787590

126. Bril M. Fredrich S. Kurniawan N.A. Stimuli-responsive materials: A smart way to study dynamic cell responses Smart Mater. Med. 2022 3 257 273 10.1016/j.smaim.2022.01.010

127. Mohapatra A. Uthaman S. Park I.K. External and Internal Stimuli-Responsive Metallic Nanotherapeutics for Enhanced Anticancer Therapy Front. Mol. Biosci. 2020 7 597634 10.3389/fmolb.2020.597634 33505987 PMC7831291

128. Vinchhi P. Rawal S.U. Patel M.M. Chapter 13-External stimuli-responsive drug delivery systems Drug Delivery Devices and Therapeutic Systems Chappel E. Academic Press Cambridge, MA, USA 2021 267 288

129. Pan T. Lu D. Xin H. Li B. Biophotonic probes for bio-detection and imaging Light Sci. Appl. 2021 10 124 10.1038/s41377-021-00561-2 34108445 PMC8190087

130. Yu H. Peng Y. Yang Y. Li Z.-Y. Plasmon-enhanced light–matter interactions and applications npj Comput. Mater. 2019 5 45 10.1038/s41524-019-0184-1

131. Kinney M.A. McDevitt T.C. Emerging strategies for spatiotemporal control of stem cell fate and morphogenesis Trends Biotechnol. 2013 31 78 84 10.1016/j.tibtech.2012.11.001 23219200 PMC3557560

132. Chagri S. Ng D.Y.W. Weil T. Designing bioresponsive nanomaterials for intracellular self-assembly Nat. Rev. Chem. 2022 6 320 338 10.1038/s41570-022-00373-x 37117928 PMC8972907

133. Egan P. Sinko R. LeDuc P.R. Keten S. The role of mechanics in biological and bio-inspired systems Nat. Commun. 2015 6 7418 10.1038/ncomms8418 26145480

134. Zhu Y.J. Chen F. pH-responsive drug-delivery systems Chem. Asian J. 2015 10 284 305 10.1002/asia.201402715 25303435

135. Hiruta Y. Poly(N-isopropylacrylamide)-based temperature- and pH-responsive polymer materials for application in biomedical fields Polym. J. 2022 54 1419 1430 10.1038/s41428-022-00687-z

136. Wei M. Gao Y. Li X. Serpe M.J. Stimuli-responsive polymers and their applications Polym. Chem. 2017 8 127 143 10.1039/c6py01585a

137. Wagner J. Gößl D. Ustyanovska N. Xiong M. Hauser D. Zhuzhgova O. Hočevar S. Taskoparan B. Poller L. Datz S. Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice ACS Nano 2021 15 4450 4466 10.1021/acsnano.0c08384 33648336

138. Yang K.N. Zhang C.Q. Wang W. Wang P.C. Zhou J.P. Liang X.J. pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment Cancer Biol. Med. 2014 11 34 43 10.7497/j.issn.2095-3941.2014.01.003 24738037 PMC3969802

139. Vargason A.M. Anselmo A.C. Mitragotri S. The evolution of commercial drug delivery technologies Nat. Biomed. Eng. 2021 5 951 967 10.1038/s41551-021-00698-w 33795852

140. Zimlichman E. Nicklin W. Aggarwal R. Bates D.W. Health care 2030: The coming transformation NEJM Catal. Innov. Care Deliv. 2021 2

141. Boone C.G. Pickett S.T.A. Bammer G. Bawa K. Dunne J.A. Gordon I.J. Hart D. Hellmann J. Miller A. New M. Preparing interdisciplinary leadership for a sustainable future Sustain. Sci. 2020 15 1723 1733 10.1007/s11625-020-00823-9 32837574 PMC7261256

142. Brain D. Plant-Hately A. Heaton B. Arshad U. David C. Hedrich C. Owen A. Liptrott N.J. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19 Adv. Drug Deliv. Rev. 2021 178 113848 10.1016/j.addr.2021.113848 34182016 PMC8233062

143. Mehta M. Bui T.A. Yang X. Aksoy Y. Goldys E.M. Deng W. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development ACS Mater. Au 2023 3 600 619 10.1021/acsmaterialsau.3c00032 38089666 PMC10636777

144. Syama K. Jakubek Z.J. Chen S. Zaifman J. Tam Y.Y.C. Zou S. Development of lipid nanoparticles and liposomes reference materials (II): Cytotoxic profiles Sci. Rep. 2022 12 18071 10.1038/s41598-022-23013-2 36302886 PMC9610362

145. Wang S. Chen Y. Guo J. Huang Q. Liposomes for Tumor Targeted Therapy: A Review Int. J. Mol. Sci. 2023 24 2643 10.3390/ijms24032643 36768966 PMC9916501

146. Pandey S. Shaikh F. Gupta A. Tripathi P. Yadav J.S. A Recent Update: Solid Lipid Nanoparticles for Effective Drug Delivery Adv. Pharm. Bull. 2022 12 17 33 10.34172/apb.2022.007 35517874 PMC9012924

147. Gull N. Arshad F. Naikoo G.A. Hassan I.U. Pedram M.Z. Ahmad A. Aljabali A.A.A. Mishra V. Satija S. Charbe N. Recent advances in anticancer activity of novel plant extracts and compounds from Curcuma longa in hepatocellular carcinoma J. Gastrointest. Cancer 2023 54 368 390 10.1007/s12029-022-00809-z 35285010 PMC8918363

148. Obeid M.A. Alsaadi M. Aljabali A.A. Recent updates in curcumin delivery J. Liposome Res. 2023 33 53 64 10.1080/08982104.2022.2086567 35699160

149. Tayeb H.H. Felimban R. Almaghrabi S. Hasaballah N. Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks Colloid Interface Sci. Commun. 2021 45 100533 10.1016/j.colcom.2021.100533 34692429 PMC8526445

150. Zhang Z. Yao S. Hu Y. Zhao X. Lee R.J. Application of lipid-based nanoparticles in cancer immunotherapy Front. Immunol. 2022 13 967505 10.3389/fimmu.2022.967505 36003395 PMC9393708

151. Bunea A.-I. Harloff-Helleberg S. Taboryski R. Nielsen H.M. Membrane interactions in drug delivery: Model cell membranes and orthogonal techniques Adv. Colloid Interface Sci. 2020 281 102177 10.1016/j.cis.2020.102177 32417568

152. Mitchell M.J. Billingsley M.M. Haley R.M. Wechsler M.E. Peppas N.A. Langer R. Engineering precision nanoparticles for drug delivery Nat. Rev. Drug Discov. 2021 20 101 124 10.1038/s41573-020-0090-8 33277608 PMC7717100

153. Zhu Y. Ma J. Shen R. Lin J. Li S. Lu X. Stelzel J.L. Kong J. Cheng L. Vuong I. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity Nat. Biomed. Eng. 2023 1 17 10.1038/s41551-023-01131-0 38082180 PMC11162325

154. Shi Y. Lu A. Wang X. Belhadj Z. Wang J. Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives Acta Pharm. Sin. B 2021 11 2396 2415 10.1016/j.apsb.2021.05.002 34522592 PMC8424287

155. Tenchov R. Bird R. Curtze A.E. Zhou Q. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement ACS Nano 2021 15 16982 17015 10.1021/acsnano.1c04996 34181394

156. Wang D. Ye Q. Gu H. Chen Z. The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies Front. Oncol. 2022 12 984560 10.3389/fonc.2022.984560 36172157 PMC9510836

157. Alhariri M. Azghani A. Omri A. Liposomal antibiotics for the treatment of infectious diseases Expert Opin. Drug Deliv. 2013 10 1515 1532 10.1517/17425247.2013.822860 23886421

158. Yu Y. Gao L. Wang Y. Xu B. Maswikiti E.P. Li H. Zheng P. Tao P. Xiang L. Gu B. A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids Front. Oncol. 2021 11 751086 10.3389/fonc.2021.751086 34722305 PMC8551635

159. Poon M.M.L. Farber D.L. The Whole Body as the System in Systems Immunology iScience 2020 23 101509 10.1016/j.isci.2020.101509 32920485 PMC7491152

160. Tsakiri M. Zivko C. Demetzos C. Mahairaki V. Lipid-based nanoparticles and RNA as innovative neuro-therapeutics Front. Pharm. 2022 13 900610 10.3389/fphar.2022.900610 PMC9395673 36016560

161. Dacoba T.G. Olivera A. Torres D. Crecente-Campo J. Alonso M.J. Modulating the immune system through nanotechnology Semin. Immunol. 2017 34 78 102 10.1016/j.smim.2017.09.007 29032891 PMC5774666

162. Elmowafy M. Shalaby K. Elkomy M.H. Alsaidan O.A. Gomaa H.A.M. Abdelgawad M.A. Mostafa E.M. Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges Polymers 2023 15 1123 10.3390/polym15051123 36904364 PMC10007077

163. Koirala P. Chen S.-P.R. Boer J.C. Khalil Z.G. Deceneux C. Goodchild G. Lu L. Faruck M.O. Shalash A.O. Bashiri S. Polymeric Nanoparticles as a Self-Adjuvanting Peptide Vaccine Delivery System: The Role of Shape Adv. Funct. Mater. 2023 33 2209304 10.1002/adfm.202209304

164. Elmowafy E.M. Tiboni M. Soliman M.E. Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles J. Pharm. Investig. 2019 49 347 380 10.1007/s40005-019-00439-x

165. Harugade A. Sherje A.P. Pethe A. Chitosan: A review on properties, biological activities and recent progress in biomedical applications React. Funct. Polym. 2023 191 105634 10.1016/j.reactfunctpolym.2023.105634

166. De Jong W.H. Borm P.J. Drug delivery and nanoparticles:applications and hazards Int. J. Nanomed. 2008 3 133 149 10.2147/ijn.s596 18686775 PMC2527668

167. Adepu S. Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions Molecules 2021 26 5905 10.3390/molecules26195905 34641447 PMC8512302

168. Afzal O. Altamimi A.S.A. Nadeem M.S. Alzarea S.I. Almalki W.H. Tariq A. Mubeen B. Murtaza B.N. Iftikhar S. Riaz N. Nanoparticles in Drug Delivery: From History to Therapeutic Applications Nanomaterials 2022 12 4494 10.3390/nano12244494 36558344 PMC9781272

169. Yoo Y.J. Lee C.H. Park S.H. Lim Y.T. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy J. Control. Release 2022 343 564 583 10.1016/j.jconrel.2022.01.047 35124126

170. Tng D.J.H. Low J.G.H. Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses Antivir. Res 2023 210 105488 10.1016/j.antiviral.2022.105488 36566118 PMC9776486

171. Barroso M.M. Quantum dots in cell biology J. Histochem. Cytochem. 2011 59 237 251 10.1369/0022155411398487 21378278 PMC3201154

172. Alshammari B.H. Lashin M.M.A. Mahmood M.A. Al-Mubaddel F.S. Ilyas N. Rahman N. Sohail M. Khan A. Abdullaev S.S. Khan R. Organic and inorganic nanomaterials: Fabrication, properties and applications RSC Adv. 2023 13 13735 13785 10.1039/d3ra01421e 37152571 PMC10162010

173. Anselmo A.C. Mitragotri S. A Review of Clinical Translation of Inorganic Nanoparticles AAPS J. 2015 17 1041 1054 10.1208/s12248-015-9780-2 25956384 PMC4540735

174. Mohammapdour R. Ghandehari H. Mechanisms of immune response to inorganic nanoparticles and their degradation products Adv. Drug Deliv. Rev. 2022 180 114022 10.1016/j.addr.2021.114022 34740764 PMC8898339

175. Reddy N. Hernandez-Ilizaliturri F.J. Deeb G. Roth M. Vaughn M. Knight J. Wallace P. Czuczman M.S. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo Br. J. Haematol. 2008 140 36 45 10.1111/j.1365-2141.2007.06841.x 17995965

176. Liu Q. Guan J. Song R. Zhang X. Mao S. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants Acta Biomater. 2022 140 76 87 10.1016/j.actbio.2021.11.034 34843949

177. Fan T. Zhang M. Yang J. Zhu Z. Cao W. Dong C. Therapeutic cancer vaccines: Advancements, challenges, and prospects Signal Transduct. Target. Ther. 2023 8 450 10.1038/s41392-023-01674-3 38086815 PMC10716479

178. Meng H. Leong W. Leong K.W. Chen C. Zhao Y. Walking the line: The fate of nanomaterials at biological barriers Biomaterials 2018 174 41 53 10.1016/j.biomaterials.2018.04.056 29778981 PMC5984195

179. Shiravand Y. Khodadadi F. Kashani S.M.A. Hosseini-Fard S.R. Hosseini S. Sadeghirad H. Ladwa R. O’Byrne K. Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy Curr. Oncol. 2022 29 3044 3060 10.3390/curroncol29050247 35621637 PMC9139602

180. Yoon M.S. Lee Y.J. Shin H.J. Park C.W. Han S.B. Jung J.K. Kim J.S. Shin D.H. Recent Advances and Challenges in Controlling the Spatiotemporal Release of Combinatorial Anticancer Drugs from Nanoparticles Pharmaceutics 2020 12 1156 10.3390/pharmaceutics12121156 33261219 PMC7759840

181. Cheng Z. Li M. Dey R. Chen Y. Nanomaterials for cancer therapy: Current progress and perspectives J. Hematol. Oncol. 2021 14 85 10.1186/s13045-021-01096-0 34059100 PMC8165984

182. Yoo J.Y. Groer M. Dutra S.V.O. Sarkar A. McSkimming D.I. Gut Microbiota and Immune System Interactions Microorganisms 2020 8 1587 10.3390/microorganisms8101587 33076307 PMC7602490

183. Turkmen Koc S.N. Rezaei Benam S. Aral I.P. Shahbazi R. Ulubayram K. Gold nanoparticles-mediated photothermal and photodynamic therapies for cancer Int. J. Pharm. 2024 655 124057 10.1016/j.ijpharm.2024.124057 38552752

184. Pisetsky D.S. Pathogenesis of autoimmune disease Nat. Rev. Nephrol. 2023 19 509 524 10.1038/s41581-023-00720-1 37165096 PMC10171171

185. Yetisgin A.A. Cetinel S. Zuvin M. Kosar A. Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications Molecules 2020 25 2193 10.3390/molecules25092193 32397080 PMC7248934

186. Diez-Pascual A.M. Rahdar A. Functional Nanomaterials in Biomedicine: Current Uses and Potential Applications ChemMedChem 2022 17 e202200142 10.1002/cmdc.202200142 35729066 PMC9544115

187. Wang D.C. Wang X. Discovery in clinical and translational medicine Clin. Transl. Med. 2021 11 e568 10.1002/ctm2.568 34709762 PMC8521278

188. Su S. Kang P.M. Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems Pharmaceutics 2020 12 837 10.3390/pharmaceutics12090837 32882875 PMC7559885

189. Chountoulesi M. Demetzos C. Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System Brain Sci. 2020 10 338 10.3390/brainsci10060338 32498357 PMC7349417

190. Walkey C.D. Chan W.C.W. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment Chem. Soc. Rev. 2012 41 2780 2799 10.1039/C1CS15233E 22086677

191. Peate I. Pathophysiology applied to nursing: The basis for disease and illness Br. J. Nurs. 2022 31 72 74 10.12968/bjon.2022.31.2.72 35094546

192. Ezike T.C. Okpala U.S. Onoja U.L. Nwike C.P. Ezeako E.C. Okpara O.J. Okoroafor C.C. Eze S.C. Kalu O.L. Odoh E.C. Advances in drug delivery systems, challenges and future directions Heliyon 2023 9 e17488 10.1016/j.heliyon.2023.e17488 37416680 PMC10320272

193. van Leent M.M.T. Priem B. Schrijver D.P. de Dreu A. Hofstraat S.R.J. Zwolsman R. Beldman T.J. Netea M.G. Mulder W.J.M. Regulating trained immunity with nanomedicine Nat. Rev. Mater. 2022 7 465 481 10.1038/s41578-021-00413-w

194. Yuan C. Liu Y. Wang T. Sun M. Chen X. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy ACS Biomater. Sci. Eng. 2020 6 4774 4798 10.1021/acsbiomaterials.0c00804 33455212

195. Kyriakides T.R. Raj A. Tseng T.H. Xiao H. Nguyen R. Mohammed F.S. Halder S. Xu M. Wu M.J. Bao S. Biocompatibility of nanomaterials and their immunological properties Biomed. Mater. 2021 16 042005 10.1088/1748-605X/abe5fa 33578402 PMC8357854

196. Egbuna C. Parmar V.K. Jeevanandam J. Ezzat S.M. Patrick-Iwuanyanwu K.C. Adetunji C.O. Khan J. Onyeike E.N. Uche C.Z. Akram M. Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology J. Toxicol. 2021 2021 9954443 10.1155/2021/9954443 34422042 PMC8376461

197. Fadeel B. Farcal L. Hardy B. Vázquez-Campos S. Hristozov D. Marcomini A. Lynch I. Valsami-Jones E. Alenius H. Savolainen K. Advanced tools for the safety assessment of nanomaterials Nat. Nanotechnol. 2018 13 537 543 10.1038/s41565-018-0185-0 29980781

198. Mukherjee P. Roy S. Ghosh D. Nandi S.K. Role of animal models in biomedical research: A review Lab. Anim. Res. 2022 38 18 10.1186/s42826-022-00128-1 35778730 PMC9247923

199. Kumar V. Sharma N. Maitra S.S. In vitro and in vivo toxicity assessment of nanoparticles Int. Nano Lett. 2017 7 243 256 10.1007/s40089-017-0221-3

200. Lukin I. Erezuma I. Desimone M.F. Zhang Y.S. Dolatshahi-Pirouz A. Orive G. Nanomaterial-based drug delivery of immunomodulatory factors for bone and cartilage tissue engineering Biomater. Adv. 2023 154 213637 10.1016/j.bioadv.2023.213637 37778293

201. Fam S.Y. Chee C.F. Yong C.Y. Ho K.L. Mariatulqabtiah A.R. Tan W.S. Stealth Coating of Nanoparticles in Drug-Delivery Systems Nanomaterials 2020 10 787 10.3390/nano10040787 32325941 PMC7221919

202. Lee D. Huntoon K. Lux J. Kim B.Y.S. Jiang W. Engineering nanomaterial physical characteristics for cancer immunotherapy Nat. Rev. Bioeng. 2023 1 499 517 10.1038/s44222-023-00047-3

203. Hassan S. Prakash G. Ozturk A. Saghazadeh S. Sohail M.F. Seo J. Dockmeci M. Zhang Y.S. Khademhosseini A. Evolution and Clinical Translation of Drug Delivery Nanomaterials Nano Today 2017 15 91 106 10.1016/j.nantod.2017.06.008 29225665 PMC5720147